The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma

描述（由申请人提供）：来自德克萨斯大学安德森癌症中心的这一竞争更新孢子在皮肤癌中的总体目标是促进黑色素瘤预防、检测和治疗方面的创新转化研究，从而消除这种疾病。这个孢子旨在通过召集一群有才华的科学家来实现这一目标，他们致力于将黑色素瘤特异性的发现从实验室转化为临床，以及从临床到实验室。德克萨斯大学安德森癌症中心将消除黑色素瘤作为一种健康风险作为优先事项，并于1998年建立了黑色素瘤多学科研究项目，以支持跨越传统行政边界的培训和研究。该项目提供的资源和结构使我们在2004年成功资助了第一个完全致力于黑色素瘤的孢子，这使我们能够进一步推进几个翻译主题，并为更新申请提供基础。这个黑素瘤的孢子提出了五个转化项目，其中四个包括治疗方案，将在连续几年开始，并利用我们庞大的黑素瘤患者群体。五个项目和四个方案由三个核心提供服务：行政(A)，信息学，组织资源和病理学(B)和生物静力学和生物信息学(C)。发展研究计划（DRP）和职业发展计划（CDP）继续作为我们孢子的成功方面，因为每个新项目都包含至少一名DRP/CDP获奖者作为新的联合领导者。五个拟议的项目涉及特异性免疫刺激toll样受体（TLR）的激活（#1）；抑制pSTAT3以控制集中在中枢神经系统的黑色素瘤转移（#2）；阐明黑色素瘤jnos相关炎症，以开发预后标志和靶向治疗（#3）；使用纳米脂质体技术全身递送血管生成抑制剂（#4）；以及免疫和炎症的遗传机制，以产生综合风险模型，作为基于人群的项目的一部分（#5）。通过这个研究项目，在德克萨斯大学安德森癌症中心的全力支持下，这个孢子旨在对黑色素瘤患者的预防、检测和治疗产生重大影响。

DESCRIPTION (provided by applicant): The overall goal of this competing renewal SPORE in skin Cancer from The University of Texas M.D. Anderson Cancer Center is to facilitate innovative translational research in the prevention, detection and treatment of melanoma leading to the elimination of the disease. This SPORE aims to achieve this goal by assembling a talented group of scientists who are committed to the translation of melanoma-specific findings from the laboratory to the clinic as well as from the clinic to the laboratory. The University of Texas M.D. Anderson Cancer Center has prioritized the elimination of melanoma as a health risk, and to this end established in 1998, a Multidisciplinary Research Program in Melanoma to support training and research across traditional administrative boundaries. The program provided resources and a structure that led to our successful funding in 2004 for the first SPORE dedicated entirely to Melanoma, which allowed us to further advance along several translational themes and provide a basis for this renewal application. This SPORE in Melanoma proposes five translational projects, four of which included treatment protocols to begin in successive years and takes advantage of our large melanoma patient population. The five projects and four protocols are served by three cores: Administrative (A), Informatics, Tissue Resource, and Pathology (B), and Biostatics and Bioinformatics (C). The Developmental Research Program (DRP) and Career Development Program (CDP) continue as successful aspects of our SPORE as each new project incorporates at least one DRP/CDP awardee as a new Co-Leader. The five proposed projects address activation of Toll-Like Receptors (TLR) for specific immune stimulation (#1); inhibition of pSTAT3 for control of melanoma metastasis focused in the CNS (#2); elucidation of melanoma JNOS-related inflammation for development of a prognostic signature as well as a target therapy (#3); systemic deliver of angiogenesis inhibitors using nanoliposomal technology (#4); and genetic mechanisms of immunity and inflammation to generate an integrated risk model as part of a population based project (#5). Through this research program and with the full support of The University of Texas M.D. Anderson Cancer Center, this SPORE aims to make a significant impact toward the prevention, detection, and treatment of melanoma in patients.